Literature DB >> 28234353

Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

S Nghiem-Buffet1,2, S Baillif3, S Regnier4, A Skelly5, N Yu6, A Sodi7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28234353      PMCID： PMC5519263          DOI： 10.1038/eye.2017.15

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  8 in total

1.  A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.

Authors:  David G Callanan; Anat Loewenstein; Sunil S Patel; Pascale Massin; Borja Corcóstegui; Xiao-Yan Li; Jenny Jiao; Yehia Hashad; Scott M Whitcup
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-08       Impact factor: 3.117

2.  Response to 'Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the U.S.A.'.

Authors:  A Lotery; S Regnier
Journal:  Eye (Lond)       Date:  2015-05-15       Impact factor: 3.775

3.  Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the U.S.A.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2015-05-15       Impact factor: 3.775

4.  Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2017-03-17       Impact factor: 3.775

5.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2010-04-09       Impact factor: 12.079

6.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  Peter A Campochiaro; Jeffrey S Heier; Leonard Feiner; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2010-04-15       Impact factor: 12.079

7.  Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA.

Authors:  A J Lotery; S Regnier
Journal:  Eye (Lond)       Date:  2015-01-09       Impact factor: 3.775

8.  Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

Authors:  S Nghiem-Buffet; S Baillif; S Regnier; A Skelly; N Yu; A Sodi
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.